Announced details
Commercialisation by drug discovery and medical startups, overseas expansion and FDA response
Our representative director, president and CEO is scheduled to speak at an online seminar hosted by JBA. Capital, personnel and business relationships: Not disclosed.
A general incorporated foundation. Location, representative, capital and year established: Not disclosed.
Capacity: 500 people
Free of charge
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | oremepermin alfa (オレメペルミン アルファ), HGF protein therapeutic |
| Counterparty | Japan Bioindustry Association (JBA) |
| Counterparty overview | A general incorporated foundation. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | Our representative director, president and CEO is scheduled to speak at an online seminar hosted by JBA. Capital, personnel and business relationships: Not disclosed. |
| Offering price | Free of charge |
| Launch date | 2 November 2026 (scheduled seminar date) |
| Applicable area | Commercialisation by drug discovery and medical startups, overseas expansion and FDA response |
| Location scale | Capacity: 500 people |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To discuss the challenges faced by drug discovery and medical startups in commercialisation and overseas expansion, how to overcome them, and deepen understanding of our overseas expansion and commercialisation strategies.